Nagilactone B NEW
| Price | $1298 |
| Package | 2mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-27 |
Product Details
| Product Name: Nagilactone B | CAS No.: 19891-51-1 |
| Supply Ability: 10g | Release date: 2025/10/27 |
Product Introduction
Bioactivity
| Name | Nagilactone B |
| Description | Nagilactone B is extracted from the root bark of Podocarpus nagi and it also is a liver X receptor (LXR) agonist. |
| In vitro | Nagilactone B (NLB) significantly ameliorates intracellular lipid accumulation. Nagilactone B (0.02, 0.1, and 0.5?μM) markedly promotes cholesterol efflux to extracellular apolipoprotein A-I (apoA-I) and high density lipoprotein (HDL) with maximal 5.72- (P<0.05) and 2.34-fold (P<0.01), respectively. RAW264.7 cells are co-incubated with oxLDL (20?μg/mL) and Nagilactone B (0.02, 0.1, and 0.5?μM) for 24?h. ORO positive areas are reduced by 30.05±7.49 (P<0.01), 47.25±5.39 (P<0.001), and 48.65±7.44% (P<0.001) in Nagilactone B (0.02, 0.1, and 0.5 μM)-treated groups, respectively . |
| In vivo | Nagilactone B (NLB) inhibits atherosclerosis in apoE-/- mice by inducing ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) mediated cholesterol efflux in macrophages. Nagilactone B treatment (10 and 30 mg/kg/day) obviously decreases en face aortic lesions, compared with the HFD group by 54.96±10.06% (P<0.01), 71.50±15.37% (P<0.001) in both NLB (L) and NLB (H) groups. In particular, Nagilactone B markedly attenuates atherosclerotic plaque lesion areas in the aortic arch aorta, thoracic aorta, and abdominal aorta [P<0.01 in NLB (H) group]. Male apoE-deficient mice on C57BL/6J background receive Nagilactone B (10 and 30?mg/kg) for 12 weeks. Compared with the model group, Nagilactone B treatment (10 and 30?mg/kg) significantly decreases en face lesions of total aorta areas. Six-week-old male apoE-/- mice on an HFD are randomized to receive Atorvastatin (10 mg/kg/day), Nagilactone B (10 and 30?mg/kg/day), or CMC-Na for 12 weeks. Mice on a chow diet are administered CMC-Na as the normal diet control group . |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Nagilactone B | LXR |
| Inhibitors Related | SR9243 | GW6340 | T0901317 | GSK3987 | Taraxasterol | SR9238 | GSK2033 | BE1218 | (20S)-Protopanaxatriol | IMB-808 | GW3965 hydrochloride | Rovazolac |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $1150.00/50g |
VIP2Y
|
R&D Scientific Inc.
|
2025-11-24 | |
| $0.00/1kg |
VIP1Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2025-04-14 | |
| $1.30/1g |
VIP6Y
|
Career Henan Chemica Co
|
2020-10-27 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY